116719-24-5

Basic information

• Product Name: 2-(4-fluorophenyl)-1-(2,3,4-trihydroxyphenyl)ethanone
• Synonyms: 2-(4-fluorophenyl)-1-(2,3,4-trihydroxyphenyl)ethanone
• CAS NO: 116719-24-5
• Molecular Weight: 262.237
• Mol File: 116719-24-5.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 2-(4-fluorophenyl)-1-(2,3,4-trihydroxyphenyl)ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-fluorophenyl)-1-(2,3,4-trihydroxyphenyl)ethanone(116719-24-5)
• EPA Substance Registry System: 2-(4-fluorophenyl)-1-(2,3,4-trihydroxyphenyl)ethanone(116719-24-5)

Safety Data

• Hazardous Substances Data: 116719-24-5(Hazardous Substances Data)

Upstream product

• 459-22-3 4-fluorophenylacetonitrile 
• 87-66-1 2-hydroxyresorcinol 
• 405-50-5 p-Fluorophenylacetic acid 

Downstream Products

• 227095-01-4 3-(4-fluoro-phenyl)-7,8-dihydroxy-2-methyl-chromen-4-one 
• 1224164-29-7 4-(2-(4-fluorophenyl)-1-(4-hydroxyphenylimino)ethyl)benzene-1,2,3-triol 
• 1224164-25-3 4-(2-(4-fluorophenyl)-1-(p-tolylimino)ethyl)benzene-1,2,3-triol 
• 1224164-27-5 4-(1-(4-chlorophenylimino)-2-(4-fluorophenyl)ethyl)benzene-1,2,3-triol 
• 1224164-28-6 4-(2-(4-fluorophenyl)-1-(4-nitrophenylimino)ethyl)benzene-1,2,3-triol 
• 1224164-26-4 4-(1-(4-bromophenylimino)-2-(4-fluorophenyl)ethyl)benzene-1,2,3-triol 
• 116719-22-3 3-(4-fluorophenyl)-7,8-dihydroxy-4H-chromen-4-one 
• 1241384-49-5 1-(2,3-dihydroxy-4-(2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethoxy)phenyl)-2-(4-fluorophenyl)ethanone 
• 1155265-01-2 2-(4-fluorophenyl)-1-(2,3,4-trihydroxyphenyl)ethanone oxime 
• 227095-03-6 3-(4-fluoro-phenyl)-7,8-dihydroxy-2-trifluoromethyl-chromen-4-one 
• 227094-99-7 acetic acid 7-acetoxy-3-(4-fluoro-phenyl)-2-methyl-4-oxo-4H-chromen-8-yl ester 
• 1219800-80-2 4-(4-fluorophenethyl)phen-1,2,3-triol 

Relevant articles and documents

Discovery and Development of Small-Molecule Inhibitors of Glycogen Synthase

The overaccumulation of glycogen appears as a hallmark in various glycogen storage diseases (GSDs), including Pompe, Cori, Andersen, and Lafora disease. Accumulating evidence suggests that suppression of glycogen accumulation represents a potential therapeutic approach for treating these GSDs. Using a fluorescence polarization assay designed to screen for inhibitors of the key glycogen synthetic enzyme, glycogen synthase (GS), we identified a substituted imidazole, (rac)-2-methoxy-4-(1-(2-(1-methylpyrrolidin-2-yl)ethyl)-4-phenyl-1H-imidazol-5-yl)phenol (H23), as a first-in-class inhibitor for yeast GS 2 (yGsy2p). Data from X-ray crystallography at 2.85 ?, as well as kinetic data, revealed that H23 bound within the uridine diphosphate glucose binding pocket of yGsy2p. The high conservation of residues between human and yeast GS in direct contact with H23 informed the development of around 500 H23 analogs. These analogs produced a structure-activity relationship profile that led to the identification of a substituted pyrazole, 4-(4-(4-hydroxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)pyrogallol, with a 300-fold improved potency against human GS. These substituted pyrazoles possess a promising scaffold for drug development efforts targeting GS activity in GSDs associated with excess glycogen accumulation.

Design and synthesis of novel deoxybenzoin derivatives as FabH inhibitors and anti-inflammatory agents

β-Ketoacyl-acyl carrier protein synthase III (FabH) catalyzes the initial step of fatty acid biosynthesis via a type II fatty acid synthase in most bacteria. The important role of this essential enzyme combined with its unique structural features and ubiq

Design, synthesis, and immunosuppressive activity of new deoxybenzoin derivatives

In the search for potential immunosuppressive agents with high efficacy and low toxicity, a series of new deoxybenzoins were synthesized and evaluated for their cytotoxicity and immunosuppressive activity. Among the synthesized compounds, four deoxybenzoi